Loading
Life sciences · Journal article
Synthetic and Systems Biotechnology · May 21, 2026
A consensus or society position rather than new primary data.
This is a systems engineering-focused narrative review of eukaryotic cell-free protein synthesis (CFPS) platforms, examining host chassis diversification, core component optimization, material integration, and emerging applications in synthetic biology. It synthesizes advances from the past 50 years and proposes engineering strategies to address standardization and cost barriers, but reports no primary experimental results or quantitative comparative data.
Journal article. Eukaryotic cell-free protein synthesis platforms and their applications in synthetic biology, biomedical, and industrial contexts.. China (author affiliations: Shenyang Normal University, Tsinghua University)..
Eukaryotic CFPS systems support complex post-translational modifications and molecular chaperone networks, enabling synthesis of functional multi-domain complex proteins lacking in prokaryotic CFPS. Diverse eukaryotic chassis have been developed—from mammalian cells, fungi, plants, insects, to protozoa—offering customized cost-effective platforms. Advanced materials (porous frameworks, hydrogels, membrane mimics) and reactor technologies have enabled evolution from microbatch to high-throughput microfluidics and portable freeze-drying modes.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review provides a comprehensive framework for researchers and biotech practitioners designing eukaryotic CFPS systems for complex protein expression and biomanufacturing. It identifies current bottlenecks (cost, standardization, scalability) and proposes integration of AI and synthetic biology tools for rational design, guiding technology development rather than clinical decision-making.
A comprehensive narrative review synthesizing advances in eukaryotic cell-free protein synthesis technology, chassis diversity, and engineering strategies—informative for researchers and practitioners but not reporting primary experimental data or comparative trials.
As stated by the source record.
This review provides a comprehensive framework for researchers and biotech practitioners designing eukaryotic CFPS systems for complex protein expression and biomanufacturing. It identifies current bottlenecks (cost, standardization, scalability) and proposes integration of AI and synthetic biology tools for rational design, guiding technology development rather than clinical decision-making.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The eukaryotic cell-free protein synthesis (CFPS) system, endowed with intrinsic post-translational modification capabilities and a complex molecular chaperone network, efficiently synthesizes functional proteins with correct conformation and biological activity. This effectively compensates for the structural limitations of prokaryotic systems in expressing complex eukaryotic proteins. This paper aims to comprehensively review and analyze the latest advances in the field of eukaryotic CFPS from a systems engineering perspective. The paper delves into the diversification of host chassis, rational design of core reaction components, and the pivotal role of novel biomaterial integration and high-throughput reaction equipment development in system reconfiguration. At the application level, it summarizes the platform's latest achievements, including elucidation of fundamental mechanisms, complex protein engineering, and metabolic synthesis. It particularly highlights its potential in emerging areas such as the construction of artificial cells, the development of bioelectronic interfaces, and the design of microarray chips. Furthermore, addressing the current standardization and cost bottlenecks hindering industrialization, this paper proposes a solution strategy based on artificial intelligence and synthetic biology tools, aligning with the shift from empirical trial-and-error to rational design paradigms. By integrating the current technological landscape with emerging trends, this review aims to provide theoretical references and practical guidance for constructing an economical, high-throughput eukaryotic cell-free biomanufacturing platform.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.